NeuroPace (NPCE) EBITDA (2020 - 2026)

NeuroPace has reported EBITDA for 7 years, with the latest figure at -$5.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 8.18% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$16.8 million (up 18.48% YoY), and the FY2025 full-year result was -$16.3 million, up 24.61% from the prior year.
• EBITDA for Q1 2026 stood at -$5.6 million, down from -$1.8 million in the prior quarter.
• The five-year high for EBITDA was -$1.8 million in Q4 2025, with the low at -$13.2 million in Q2 2022.
• Average EBITDA over 5 years is -$7.5 million, with a median of -$7.3 million recorded in 2023.
• Year-over-year, EBITDA plunged 54.52% in 2022 and soared 51.63% in 2025.
• Tracing NPCE's EBITDA over 5 years: stood at -$10.9 million in 2022, then surged by 43.22% to -$6.2 million in 2023, then surged by 41.08% to -$3.7 million in 2024, then soared by 51.63% to -$1.8 million in 2025, then slumped by 215.11% to -$5.6 million in 2026.
• The last three EBITDA figures came in at -$5.6 million (Q1 2026), -$1.8 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.

Peer Comparison